home / stock / vyne / vyne news


VYNE News and Press, VYNE Therapeutics Inc Com From 05/15/23

Stock Information

Company Name: VYNE Therapeutics Inc Com
Stock Symbol: VYNE
Market: NASDAQ
Website: vynetherapeutics.com

Menu

VYNE VYNE Quote VYNE Short VYNE News VYNE Articles VYNE Message Board
Get VYNE Alerts

News, Short Squeeze, Breakout and More Instantly...

VYNE - FSLR, OUST and ARLO are among pre market gainers

2023-05-15 08:25:29 ET GSI Technology ( GSIT ) +210% . ARS Pharmaceuticals ( SPRY ) +78% . ImmunoPrecise Antibodies  ( IPA ) +39% . AirSculpt Technologies ( AIRS ) +37% . Meihua International Medical Technologies ( MHUA ) +37% ...

VYNE - VYNE Therapeutics GAAP EPS of -$1.74 beats by $0.87, revenue of $0.1M

2023-05-11 17:00:02 ET VYNE Therapeutics press release ( NASDAQ: VYNE ): Q1 GAAP EPS of -$1.74 beats by $0.87 . Revenue of $0.1M (-44.4% Y/Y). Research and development expenses . VYNE's research and development expenses for the quarter ended March 31, 2023 were...

VYNE - VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in ...

VYNE - VYNE Therapeutics selects lead candidate for immuno-inflammatory treatment program

2023-05-01 11:40:49 ET VYNE Therapeutics ( NASDAQ: VYNE ) has selected a lead candidate for its oral BD2-selective bromodomain and extra-terminal inhibitor program, VYN202, used to treat immuno-inflammatory conditions. VYNE exclusively licensed the BD2-selective BET inhibitors...

VYNE - VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic effect in multiple validated preclinical models of autoimmune disease IND-enabling studies a...

VYNE - NVAX, SUNW and BTBT among pre-market losers

2023-04-20 08:22:47 ET Windtree Therapeutics ( WINT ) -40% . Genius Group Limited ( GNS ) -12% . Nokia Oyj ( NOK ) -9% . on mixed Q1 earnings . Tesla ( TSLA ) -8% . after Q1 earning release . F5 ( FFIV ) -7% . after Q2 earn...

VYNE - BBBY, CTXR and HTGM among mid-day movers

2023-04-19 12:49:23 ET Gainers: SAI.TECH Global Corporation ( SAI ) +48% . Bed Bath & Beyond ( BBBY ) +40% . VYNE Therapeutics ( VYNE ) +34% . Boqii Holding Limited ( BQ ) +30% . CXApp ( CXAI ) +19% . Western Alliance Ban...

VYNE - Vyne Therapeutics Inc. (NASDAQ: VYNE) is One of Wednesday Morning's Most Active Stocks

VYNE Therapeutics Inc. (NASDAQ: VYNE) is one today's most active stocks by volume. So far today, approximately 29.8M shares of VYNE Therapeutics Inc. have been exchanged, as compared to an average 30-day volume of 20,405 shares. VYNE Therapeutics Inc., a pharmaceutical company, focuses on deve...

VYNE - 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,560%

2023-04-19 10:32:41 ET If you’re looking for penny stocks to buy now, there’s a lot to account for in the stock market today. Whether it’s the overarching recession and inflation story or the underpinnings of a potential stock market crash in 2023, emotions are ridi...

VYNE - Vyne, Ensysce top healthcare gainers; Allarity, Femasys lead losers' pack

2023-04-19 10:05:08 ET Gainers: Vyne Therapeutics ( VYNE ) +32% . Ensysce Biosciences ( ENSC ) +23% . Legend Biotech ( LEGN ) +20% . Tempest Therapeutics ( TPST ) +16% . Evoke Pharma ( EVOK ) +14% . Losers: Allarity T...

Previous 10 Next 10